Copyright Reports & Markets. All rights reserved.

Global Recombinant Plasma Proteins Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Recombinant Plasma Proteins Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Chinese Hamster Ovary (CHO) Cell Line
      • 1.4.3 Baby Hamster Kidney (BHK) Cell Line
      • 1.4.4 Human Embryonic Kidney (HEK) Cell Line
      • 1.4.5 Others
    • 1.5 Market by Application
      • 1.5.1 Global Recombinant Plasma Proteins Market Share by Application (2014-2025)
      • 1.5.2 Hemophilia A
      • 1.5.3 Hemophilia B
      • 1.5.4 Von Willebrand Disease
      • 1.5.5 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Recombinant Plasma Proteins Market Size
    • 2.2 Recombinant Plasma Proteins Growth Trends by Regions
      • 2.2.1 Recombinant Plasma Proteins Market Size by Regions (2014-2025)
      • 2.2.2 Recombinant Plasma Proteins Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Recombinant Plasma Proteins Market Size by Manufacturers
      • 3.1.1 Global Recombinant Plasma Proteins Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Recombinant Plasma Proteins Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Recombinant Plasma Proteins Market Concentration Ratio (CR5 and HHI)
    • 3.2 Recombinant Plasma Proteins Key Players Head office and Area Served
    • 3.3 Key Players Recombinant Plasma Proteins Product/Solution/Service
    • 3.4 Date of Enter into Recombinant Plasma Proteins Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Recombinant Plasma Proteins Market Size by Type (2014-2019)
    • 4.2 Global Recombinant Plasma Proteins Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Recombinant Plasma Proteins Market Size (2014-2019)
    • 5.2 Recombinant Plasma Proteins Key Players in United States
    • 5.3 United States Recombinant Plasma Proteins Market Size by Type
    • 5.4 United States Recombinant Plasma Proteins Market Size by Application

    6 Europe

    • 6.1 Europe Recombinant Plasma Proteins Market Size (2014-2019)
    • 6.2 Recombinant Plasma Proteins Key Players in Europe
    • 6.3 Europe Recombinant Plasma Proteins Market Size by Type
    • 6.4 Europe Recombinant Plasma Proteins Market Size by Application

    7 China

    • 7.1 China Recombinant Plasma Proteins Market Size (2014-2019)
    • 7.2 Recombinant Plasma Proteins Key Players in China
    • 7.3 China Recombinant Plasma Proteins Market Size by Type
    • 7.4 China Recombinant Plasma Proteins Market Size by Application

    8 Japan

    • 8.1 Japan Recombinant Plasma Proteins Market Size (2014-2019)
    • 8.2 Recombinant Plasma Proteins Key Players in Japan
    • 8.3 Japan Recombinant Plasma Proteins Market Size by Type
    • 8.4 Japan Recombinant Plasma Proteins Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Recombinant Plasma Proteins Market Size (2014-2019)
    • 9.2 Recombinant Plasma Proteins Key Players in Southeast Asia
    • 9.3 Southeast Asia Recombinant Plasma Proteins Market Size by Type
    • 9.4 Southeast Asia Recombinant Plasma Proteins Market Size by Application

    10 India

    • 10.1 India Recombinant Plasma Proteins Market Size (2014-2019)
    • 10.2 Recombinant Plasma Proteins Key Players in India
    • 10.3 India Recombinant Plasma Proteins Market Size by Type
    • 10.4 India Recombinant Plasma Proteins Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Recombinant Plasma Proteins Market Size (2014-2019)
    • 11.2 Recombinant Plasma Proteins Key Players in Central & South America
    • 11.3 Central & South America Recombinant Plasma Proteins Market Size by Type
    • 11.4 Central & South America Recombinant Plasma Proteins Market Size by Application

    12 International Players Profiles

    • 12.1 CSL Limited
      • 12.1.1 CSL Limited Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Recombinant Plasma Proteins Introduction
      • 12.1.4 CSL Limited Revenue in Recombinant Plasma Proteins Business (2014-2019)
      • 12.1.5 CSL Limited Recent Development
    • 12.2 Shire (Takeda Pharmaceutical Company Limited)
      • 12.2.1 Shire (Takeda Pharmaceutical Company Limited) Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Recombinant Plasma Proteins Introduction
      • 12.2.4 Shire (Takeda Pharmaceutical Company Limited) Revenue in Recombinant Plasma Proteins Business (2014-2019)
      • 12.2.5 Shire (Takeda Pharmaceutical Company Limited) Recent Development
    • 12.3 Octapharma
      • 12.3.1 Octapharma Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Recombinant Plasma Proteins Introduction
      • 12.3.4 Octapharma Revenue in Recombinant Plasma Proteins Business (2014-2019)
      • 12.3.5 Octapharma Recent Development
    • 12.4 Novo Nordisk
      • 12.4.1 Novo Nordisk Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Recombinant Plasma Proteins Introduction
      • 12.4.4 Novo Nordisk Revenue in Recombinant Plasma Proteins Business (2014-2019)
      • 12.4.5 Novo Nordisk Recent Development
    • 12.5 Bayer
      • 12.5.1 Bayer Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Recombinant Plasma Proteins Introduction
      • 12.5.4 Bayer Revenue in Recombinant Plasma Proteins Business (2014-2019)
      • 12.5.5 Bayer Recent Development
    • 12.6 Bioverativ Therapeutics, Inc. (Sanofi)
      • 12.6.1 Bioverativ Therapeutics, Inc. (Sanofi) Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Recombinant Plasma Proteins Introduction
      • 12.6.4 Bioverativ Therapeutics, Inc. (Sanofi) Revenue in Recombinant Plasma Proteins Business (2014-2019)
      • 12.6.5 Bioverativ Therapeutics, Inc. (Sanofi) Recent Development
    • 12.7 Aptevo Therapeutics
      • 12.7.1 Aptevo Therapeutics Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Recombinant Plasma Proteins Introduction
      • 12.7.4 Aptevo Therapeutics Revenue in Recombinant Plasma Proteins Business (2014-2019)
      • 12.7.5 Aptevo Therapeutics Recent Development
    • 12.8 Pharming Group
      • 12.8.1 Pharming Group Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Recombinant Plasma Proteins Introduction
      • 12.8.4 Pharming Group Revenue in Recombinant Plasma Proteins Business (2014-2019)
      • 12.8.5 Pharming Group Recent Development
    • 12.9 Pfizer
      • 12.9.1 Pfizer Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Recombinant Plasma Proteins Introduction
      • 12.9.4 Pfizer Revenue in Recombinant Plasma Proteins Business (2014-2019)
      • 12.9.5 Pfizer Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks-
      In 2018, the global Recombinant Plasma Proteins market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Recombinant Plasma Proteins status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Recombinant Plasma Proteins development in United States, Europe and China.

      The key players covered in this study
      CSL Limited
      Shire (Takeda Pharmaceutical Company Limited)
      Octapharma
      Novo Nordisk
      Bayer
      Bioverativ Therapeutics, Inc. (Sanofi)
      Aptevo Therapeutics
      Pharming Group
      Pfizer

      Market segment by Type, the product can be split into
      Chinese Hamster Ovary (CHO) Cell Line
      Baby Hamster Kidney (BHK) Cell Line
      Human Embryonic Kidney (HEK) Cell Line
      Others

      Market segment by Application, split into
      Hemophilia A
      Hemophilia B
      Von Willebrand Disease
      Others

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Recombinant Plasma Proteins status, future forecast, growth opportunity, key market and key players.
      To present the Recombinant Plasma Proteins development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Recombinant Plasma Proteins are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now